Pivot (invalidation): 13400.00 Our preference Long positions above 13400.00 with targets at 13503.00 & 13550.00 in extension. Alternative scenario...
Analytics & Forecasts
  • 108
15 January 2020, 09:03 #dax
Pivot (invalidation): 5.8740 Our preference Long positions above 5.8740 with targets at 5.8930 & 5.9010 in extension. Alternative scenario...
Analytics & Forecasts
  • 90
15 January 2020, 09:02
Pivot (invalidation): 0.6905 Our preference Short positions below 0.6905 with targets at 0.6880 & 0.6865 in extension. Alternative scenario...
Analytics & Forecasts
  • 88
15 January 2020, 09:01
Pivot (invalidation): 1.3075 Our preference Short positions below 1.3075 with targets at 1.3045 & 1.3030 in extension. Alternative scenario...
Analytics & Forecasts
  • 151
15 January 2020, 09:00 #usd/cad
Pivot (invalidation): 0.9690 Our preference Short positions below 0.9690 with targets at 0.9660 & 0.9640 in extension. Alternative scenario...
Analytics & Forecasts
  • 89
15 January 2020, 08:59
Pivot (invalidation): 110.10 Our preference Short positions below 110.10 with targets at 109.80 & 109.60 in extension. Alternative scenario...
Analytics & Forecasts
  • 128
15 January 2020, 08:59 #usd/jpy
Pivot (invalidation): 1.3010 Our preference Long positions above 1.3010 with targets at 1.3035 & 1.3050 in extension. Alternative scenario...
Analytics & Forecasts
  • 109
15 January 2020, 08:58 #GBP/USD
Pivot (invalidation): 1.1120 Our preference Long positions above 1.1120 with targets at 1.1135 & 1.1145 in extension. Alternative scenario...
Analytics & Forecasts
  • 113
15 January 2020, 08:56 #EUR/USD
Technology stocks pushed the S&P500 and the Nasdaq to new records on Monday, as the rush toward the equities intensified ahead of the planned signature of the phase one deal between the US and China, and the release of the big US banks’ fourth quarter earnings...
Market News
  • 127
14 January 2020, 12:36
Dare Bioscience Inc. (DARE) shares rose 79% to $1.50 after the company said it is in a licensing agreement with Bayer (BAYN.XE). Bayer may commercialize Dare's investigational contraceptive product Ovaprene in the U.S. once approved by the U.S. Food and Drug Administration, Dare said...
Market News
  • 171
14 January 2020, 12:34